01—Abstract
Summary
Summary of the 8-K filed May 28, 2025. Cited figures are marked; the original filing is the authoritative source.
Elevance Health, Inc. has filed an 8-K report to reaffirm its financial guidance for the full year 2025.
The company expects diluted earnings per share to be in the range of $28.30 to $29.00a, which includes approximately $5.85 per diluted share in net unfavorable items. Excluding these specific items, the adjusted earnings per diluted share are projected to be between $34.15 and $34.85, consistent with prior statements and not incorporating additional adjustments beyond those reported in Q1 2025. Furthermore, Elevance Health is reiterating its full-year 2025 guidance for the benefit expense ratio, targeting 89.1% with a 50 basis point margin of error.
The company also anticipates that 60%b of its adjusted shareholders' earnings per diluted share will be realized in the first half of 2025. These reaffirmations reflect management's current assessment of market conditions, operational performance, regulatory environments, and refined business assumptions. Investors are reminded that actual results may differ materially due to inherent uncertainties and risks outlined in the company's SEC filings.
02—Key points
Key Highlights
- Reaffirmation of full-year 2025 diluted earnings per share guidance between $28.30 and $29.00.
- Inclusion of approximately $5.85 per diluted share in net unfavorable items within the reported EPS guidance.
- Projected adjusted shareholders' earnings per diluted share for full year 2025 remain between $34.15 and $34.85.
- Reaffirmation of full-year 2025 benefit expense ratio guidance at 89.1% +/- 50 basis points.
- Expectation that 60% of adjusted shareholders' earnings per diluted share will be achieved in the first half of 2025.
- Guidance reflects current management views on market conditions, operational performance, and regulatory landscape.
- Company notes that actual results could materially differ from guidance due to various risks and uncertainties.
03—Questions
Frequently Asked Questions
What is the key takeaway from Elevance Health's 8-K filing on May 28, 2025?
The key takeaway is that Elevance Health is reaffirming its previously issued financial guidance for the full fiscal year 2025, signaling confidence in its operational outlook and financial projections to investors.
What are the specific earnings per share figures being reaffirmed by Elevance Health?
The company is reaffirming its diluted earnings per share guidance for 2025 to be in the range of $28.30 to $29.00. This includes about $5.85 per share in net unfavorable items. Excluding these items, the adjusted earnings per diluted share are expected to be between $34.15 and $34.85.
What is the guidance for the benefit expense ratio?
Elevance Health is reaffirming its full-year 2025 guidance for the benefit expense ratio to be 89.1%, with a margin of error of plus or minus 50 basis points.
What is the expected realization of earnings in the first half of 2025?
The company expects that approximately 60% of its adjusted shareholders' earnings per diluted share for the full year 2025 will be realized in the first half of the year.
04—Continue